Results 91 to 100 of about 6,883,814 (290)

Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

, 2020
In recent years, advances in drug therapy for head and neck squamous cell carcinoma (HNSCC) have progressed rapidly. In addition to cytotoxic anti-cancer agents such as platinum-based drug (cisplatin and carboplatin) and taxane-based drugs (docetaxel and
Naoya Kitamura, Eri Sasabe, Shinya Sento, Yasusei Kudo, Yasumasa Yoshizawa, Tetsuya Yamamoto   +5 more
core   +1 more source

Structural Insights into the SARS-CoV-2 Spike Protein and Its Implications for Antibody Resistance

Biomolecules
The COVID-19 pandemic, caused by SARS-CoV-2, has profoundly affected global health and the economy. The emergence of variants with spike mutations, particularly within the receptor-binding domain (RBD), has reduced the efficacy of many neutralizing ...
Yuichiro Yamamoto, Kohji Noguchi
doaj   +1 more source

Cancer Prevention with Molecular Targeted Therapies

International Journal of Molecular Sciences, 2022
Today, the oncologist is like a detective of the human body who, instead of a magnifying glass, uses the new tools of molecular pathology to search not only for genes or molecular targets, to be targeted with innovative anticancer therapies, but also molecular alterations that allow the identification of population groups at risk of developing tumors ...
openaire   +2 more sources

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Liver organoids: modelling complexity in homeostasis and disease

FEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Antibody targeted nanoparticles for imaging and therapy of cancer [PDF]

, 2010
The central hypothesis for this thesis is that antibody-targeted superparamagnetic iron oxide nanoparticles (SPIONs) can be used for diagnosis and therapy of cancer.
Vigor, K.L.
core  

Efficacy of various extent of resection on survival rates of patients with pilocytic astrocytoma: based on a large population

Scientific Reports
Pilocytic astrocytoma (PA) is classified as a Grade I benign neuroglial tumor. The extent of surgical resection is a critical factor influencing the prognosis for patients with PA.
Jun Su, Shanshan Guo, Zheyuan Chen, Yiming Han, Jingwang Yan, Qiyun Tang, Yu Mao, Haiqiang Zhang, Guojiang Hou, Gaopan Dong, Chao Guo, Pengfei Yang   +11 more
doaj   +1 more source

Pemigatinib combined with immunotherapy and stereotactic body radiation therapy for FGFR2 fusion-positive advanced intrahepatic cholangiocarcinoma with brain metastasis: a Case Report

Frontiers in Pharmacology
BackgroundFGFR2 fusions or rearrangements occur in 13%–20% of patients with intrahepatic cholangiocarcinoma (iCCA). Pemigatinib, a representative FGFR inhibitor, is commonly used for targeted therapy in such patients.
Jiamin Guo, Lingqi Sun, Ye Chen, Ji Ma
doaj   +1 more source

Targeted Molecular Therapy in Glioblastoma

Journal of Oncology, 2020
Festuccia, Claudio, Biordi, Assunta Leda, Tombolini, Vincenzo, Hara, Akira, Bailey, David   +4 more
openaire   +2 more sources

Epigenetic reprogramming of lineage switching in cancer

FEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Nese Atabey, Serap Erkek‐Ozhan   +4 more
wiley   +1 more source